



## SuperGen Data Presentations at American Society of Hematology (ASH) Annual Meeting

DUBLIN, Calif.--(BUSINESS WIRE)--Dec. 1, 2009-- SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of two abstracts for poster presentations on December 6, 2009 at the 51<sup>st</sup> American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.

The first presentation will review non-clinical data with the SuperGen compound SGI-1776 in therapeutic combination model systems with panobinostat, and the second presentation will discuss the early data generated from the new Axl kinase program.

The posters will be made available for viewing on the company's website [www.supergen.com](http://www.supergen.com) following the respective presentations:

**SGI-1776:** Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells  
Abstract 2651, Sunday Dec 6, 6:00 – 8:00 pm CT

**AXL:** Targeting Axl Kinase in Hematological Malignancies  
Abstract 2758, Sunday Dec 6, 6:00 – 8:00 pm CT

### About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit <http://www.supergen.com>.

Source: SuperGen, Inc.

SuperGen, Inc.  
Timothy L. Enns, 925-560-2810  
Senior Vice President  
Corporate Communications & Business Development  
[tenns@supergen.com](mailto:tenns@supergen.com)  
or  
Susanna Chau, 925-560-2845  
Manager  
Investor Relations  
[schau@supergen.com](mailto:schau@supergen.com)